Akebia Therapeutics AKBA 深 滬
等待開盤 10-08 09:30:00 美东时间
0.8734
-0.005
-0.58%
華盛通- 最 高0.8874
- 今 開0.8633
- 成交量 916.39万股
- 最 低 0.8633
- 昨 收 0.8785
- 總市值 2.42亿
- 52周最高 3.20
- 市盈率 靜 --
- 換手率 3.31%
- 52周最低 0.814
- 委 比 -70.82%
- 總股本 2.77亿
- 歷史最高 31.00
- 量 比 1.27
- 振 幅 2.74%
- 歷史最低 0.241
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted a new employee stock options for 8,400 shares on September 30, 2026, as an inducement for employment. The options, priced at $0.92 per share, vest over four years with 25% on the first anniversary and the remaining 75% quarterly thereafter, subject to continued employment. Each option has a 10-year term and aligns with Nasdaq Listing Rule 5635(c)(4).
10-01 20:05
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
SCYNEXIS appoints Todd Minga, M.D., as Senior Vice President, Research & Development. Dr. Minga brings over 20 years of experience in kidney disease and rare disorders, previously serving as Vice President, Medical Affairs and Clinical Development at Akebia Therapeutics. His expertise will support SCYNEXIS in advancing its rare disease programs, including SCY-770 for ADPKD and SCY-247. Dr. Minga expressed excitement about contributing to the Comp...
09-15 12:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.
09-08 23:38
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted a newly hired employee stock options to purchase 8,400 shares, priced at $0.92 per share, as an inducement for employment. The options vest over four years, with 25% vesting annually and the rest quarterly, subject to continued service. Each option has a 10-year term and aligns with the company's inducement award program.
09-01 20:05
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
Akebia Therapeutics, Inc. announced that its CEO, John P. Butler, and CFO/Chief Business Officer, Erik Ostrowski, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference in Boston from September 8-10, 2026. The discussions will focus on the company's commercial products and its clinical pipeline for kidney disease. Akebia, founded in 2007 and headquartered in Cambridge, Massachusetts, aims to improve the lives of those af...
09-01 12:00
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.
08-08 08:20
Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining over 100 points on Thursday. Shares of Western Digital Corp (NASDAQ:WDC) fell sharply in pre-market trading following fourth-quarter results. Western Digital reported quarterly earnings of $3.56 per share, which beat the Street...
08-06 20:04
